Tharimmune Net Income
| THAR Stock | 4.73 0.64 11.92% |
As of the 5th of February, Tharimmune has the Semi Deviation of 5.16, coefficient of variation of 726.67, and Risk Adjusted Performance of 0.1101. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tharimmune, as well as the relationship between them. Please validate Tharimmune variance, as well as the relationship between the value at risk and skewness to decide if Tharimmune is priced more or less accurately, providing market reflects its prevalent price of 4.73 per share. Given that Tharimmune has jensen alpha of 0.8719, we advise you to double-check Tharimmune's current market performance to make sure the company can sustain itself at a future point.
Tharimmune's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tharimmune's valuation are provided below:There are over one hundred eleven available fundamental trend indicators for Tharimmune, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Tharimmune's current fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/05/2026, Market Cap is likely to drop to about 2.8 M. In addition to that, Enterprise Value is likely to drop to about (876.9 K) This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -11 M | -10.4 M | |
| Net Loss | -7.6 M | -7.2 M | |
| Net Loss | -11 M | -10.4 M | |
| Net Loss | (10.82) | (11.36) |
Tharimmune | Net Income | Build AI portfolio with Tharimmune Stock |
Evaluating Tharimmune's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Tharimmune's fundamental strength.
Latest Tharimmune's Net Income Growth Pattern
Below is the plot of the Net Income of Tharimmune over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Tharimmune financial statement analysis. It represents the amount of money remaining after all of Tharimmune operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Tharimmune's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tharimmune's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (12.2 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Tharimmune Net Income Regression Statistics
| Arithmetic Mean | (4,192,666) | |
| Coefficient Of Variation | (98.31) | |
| Mean Deviation | 3,580,382 | |
| Median | (1,525,474) | |
| Standard Deviation | 4,121,936 | |
| Sample Variance | 17T | |
| Range | 10.7M | |
| R-Value | (0.82) | |
| Mean Square Error | 6T | |
| R-Squared | 0.67 | |
| Significance | 0.000063 | |
| Slope | (666,698) | |
| Total Sum of Squares | 271.8T |
Tharimmune Net Income History
Other Fundumenentals of Tharimmune
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Tharimmune Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tharimmune is extremely important. It helps to project a fair market value of Tharimmune Stock properly, considering its historical fundamentals such as Net Income. Since Tharimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tharimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tharimmune's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Tharimmune have expansion opportunities? Factors like these will boost the valuation of Tharimmune. If investors know Tharimmune will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Tharimmune demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Tharimmune is measured differently than its book value, which is the value of Tharimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Tharimmune's value that differs from its market value or its book value, called intrinsic value, which is Tharimmune's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Tharimmune's market value can be influenced by many factors that don't directly affect Tharimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tharimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tharimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Tharimmune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Tharimmune 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tharimmune's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tharimmune.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Tharimmune on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Tharimmune or generate 0.0% return on investment in Tharimmune over 90 days. Tharimmune is related to or competes with BioLineRx, GeoVax Labs, Adlai Nortye, Lunai Bioworks, SeaStar Medical, Ainos, and Apollomics. Tharimmune is entity of United States. It is traded as Stock on NASDAQ exchange. More
Tharimmune Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tharimmune's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tharimmune upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.67 | |||
| Information Ratio | 0.128 | |||
| Maximum Drawdown | 35.56 | |||
| Value At Risk | (9.64) | |||
| Potential Upside | 11.55 |
Tharimmune Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tharimmune's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tharimmune's standard deviation. In reality, there are many statistical measures that can use Tharimmune historical prices to predict the future Tharimmune's volatility.| Risk Adjusted Performance | 0.1101 | |||
| Jensen Alpha | 0.8719 | |||
| Total Risk Alpha | 0.4164 | |||
| Sortino Ratio | 0.1515 | |||
| Treynor Ratio | 1.19 |
Tharimmune February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1101 | |||
| Market Risk Adjusted Performance | 1.2 | |||
| Mean Deviation | 5.31 | |||
| Semi Deviation | 5.16 | |||
| Downside Deviation | 5.67 | |||
| Coefficient Of Variation | 726.67 | |||
| Standard Deviation | 6.71 | |||
| Variance | 45.07 | |||
| Information Ratio | 0.128 | |||
| Jensen Alpha | 0.8719 | |||
| Total Risk Alpha | 0.4164 | |||
| Sortino Ratio | 0.1515 | |||
| Treynor Ratio | 1.19 | |||
| Maximum Drawdown | 35.56 | |||
| Value At Risk | (9.64) | |||
| Potential Upside | 11.55 | |||
| Downside Variance | 32.17 | |||
| Semi Variance | 26.64 | |||
| Expected Short fall | (6.19) | |||
| Skewness | 0.5241 | |||
| Kurtosis | 0.6496 |
Tharimmune Backtested Returns
Tharimmune appears to be risky, given 3 months investment horizon. Tharimmune owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0629, which indicates the firm had a 0.0629 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Tharimmune, which you can use to evaluate the volatility of the company. Please review Tharimmune's Risk Adjusted Performance of 0.1101, coefficient of variation of 726.67, and Semi Deviation of 5.16 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Tharimmune holds a performance score of 4. The entity has a beta of 0.77, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tharimmune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tharimmune is expected to be smaller as well. Please check Tharimmune's value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether Tharimmune's existing price patterns will revert.
Auto-correlation | -0.51 |
Good reverse predictability
Tharimmune has good reverse predictability. Overlapping area represents the amount of predictability between Tharimmune time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tharimmune price movement. The serial correlation of -0.51 indicates that about 51.0% of current Tharimmune price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.51 | |
| Spearman Rank Test | -0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 0.67 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Tharimmune Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Tharimmune reported net income of (12.2 Million). This is 103.57% lower than that of the Biotechnology sector and 117.41% lower than that of the Health Care industry. The net income for all United States stocks is 102.14% higher than that of the company.
Tharimmune Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tharimmune's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tharimmune could also be used in its relative valuation, which is a method of valuing Tharimmune by comparing valuation metrics of similar companies.Tharimmune is currently under evaluation in net income category among its peers.
Tharimmune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tharimmune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tharimmune's managers, analysts, and investors.Environmental | Governance | Social |
Tharimmune Fundamentals
| Return On Equity | -2.25 | ||||
| Return On Asset | -1.0 | ||||
| Current Valuation | 209.17 M | ||||
| Shares Outstanding | 39.53 M | ||||
| Shares Owned By Insiders | 29.27 % | ||||
| Shares Owned By Institutions | 4.51 % | ||||
| Number Of Shares Shorted | 1.49 M | ||||
| Price To Book | 34.39 X | ||||
| EBITDA | (12.43 M) | ||||
| Net Income | (12.2 M) | ||||
| Total Debt | 2.41 M | ||||
| Book Value Per Share | 0.85 X | ||||
| Cash Flow From Operations | (10.9 M) | ||||
| Short Ratio | 2.67 X | ||||
| Earnings Per Share | (3.68) X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 212.28 M | ||||
| Total Asset | 3.72 M | ||||
| Retained Earnings | (36.9 M) | ||||
| Working Capital | 1.31 M | ||||
| Net Asset | 3.72 M |
About Tharimmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tharimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tharimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tharimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tharimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tharimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will appreciate offsetting losses from the drop in the long position's value.Moving against Tharimmune Stock
The ability to find closely correlated positions to Tharimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tharimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tharimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tharimmune to buy it.
The correlation of Tharimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tharimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tharimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tharimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.